Description: Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Home Page: castlebiosciences.com
CSTL Technical Analysis
505 South Friendswood Drive
Friendswood,
TX
77546
United States
Phone:
866 788 9007
Officers
| Name | Title |
|---|---|
| Mr. Derek J. Maetzold | Founder, CEO, Pres & Director |
| Mr. Frank Stokes | CFO & Treasurer |
| Ms. Kristen M. Oelschlager R.N., RN | Chief Operating Officer |
| Mr. Toby W. Juvenal | Chief Commercial Officer |
| Camilla Zuckero | Exec. Director of Investor Relations & Corp. Communications |
| Ms. Alice Bahner Izzo | Sr. VP of Marketing |
| Ms. Keli Greenberg | VP of HR & Exec. Director of HR |
| Dr. Robert W. Cook Ph.D. | Sr. VP of R&D |
| Mr. Bernhard E. Spiess | Company Sec. |
| Mr. John W. Abbott | VP & Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5916 |
| Price-to-Sales TTM: | 5.258 |
| IPO Date: | 2019-07-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 517 |